BeOne Medicines Ltd. (ONC) operating KPIs
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$370.33−1.23 (-0.33%)
Close on Oct 30, 2026Market cap $42.11BP/E 66.2Yield –
BeOne Medicines gAAP Gross Margin (% of Global Product Sales) (%)
Form 8-K EX-99.1 Earnings Releases & Form 10-Q / 10-K MD&A
Latest, Q2 2026
90.0%
Period ended Jun 30, 2026
Change on a year earlier
+2.6 pts
87.4% in Q2 2025
History
19 quarters
Since Q4 2021
Sources
15
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | GAAP Gross Margin (% of Global Product Sales) (%) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 90.0% | +2.6 pts | Form 8-K (filed 2026-08-05) ↗ |
| Q1 2026 | Mar 31, 2026 | 89.0% | +3.9 pts | Form 8-K (filed 2026-05-06) ↗ |
| Q4 2025 | Dec 31, 2025 | 90.4% | +4.8 pts | Form 8-K (filed 2026-02-26) ↗ |
| Q3 2025 | Sep 30, 2025 | 85.9% | +2.9 pts | Form 8-K (filed 2025-11-06) ↗ |
| Q2 2025 | Jun 30, 2025 | 87.4% | +2.4 pts | Form 8-K (filed 2025-08-06) ↗ |
| Q1 2025 | Mar 31, 2025 | 85.1% | +2.1 pts | Form 8-K (filed 2025-05-07) ↗ |
| Q4 2024 | Dec 31, 2024 | 85.6% | +2.4 pts | Form 8-K (filed 2026-02-26) ↗ |
| Q3 2024 | Sep 30, 2024 | 83.0% | -0.8 pts | Form 8-K (filed 2024-11-12) ↗ |
| Q2 2024 | Jun 30, 2024 | 85.0% | +2.3 pts | Form 8-K (filed 2024-08-07) ↗ |
| Q1 2024 | Mar 31, 2024 | 83.0% | +2.9 pts | Form 8-K (filed 2024-05-08) ↗ |
| Q4 2023 | Dec 31, 2023 | 83.2% | +4.9 pts | Form 8-K (filed 2025-02-27) ↗ |
| Q3 2023 | Sep 30, 2023 | 83.8% | +5.7 pts | Form 8-K (filed 2023-11-09) ↗ |
| Q2 2023 | Jun 30, 2023 | 82.7% | +6.1 pts | Form 8-K (filed 2023-08-02) ↗ |
| Q1 2023 | Mar 31, 2023 | 80.1% | +5.0 pts | Form 8-K (filed 2023-05-04) ↗ |
| Q4 2022 | Dec 31, 2022 | 78.3% | +3.0 pts | Form 8-K (filed 2024-02-26) ↗ |
| Q3 2022 | Sep 30, 2022 | 78.1% | – | Form 8-K (filed 2023-11-09) ↗ |
| Q2 2022 | Jun 30, 2022 | 76.6% | – | Form 8-K (filed 2023-08-02) ↗ |
| Q1 2022 | Mar 31, 2022 | 75.1% | – | Form 8-K (filed 2023-05-04) ↗ |
| Q4 2021 | Dec 31, 2021 | 75.3% | – | Form 8-K (filed 2023-02-27) ↗ |
Breakdown
What makes up gaap gross margin (% of global product sales)
Cite this data
StockData. (2026). BeOne Medicines GAAP Gross Margin (% of Global Product Sales) (%), quarterly Q4 2021–Q2 2026 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/gaap_gm_pct
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.